Search Results - "RATZIU, VLAD"

A critical review of endpoints for non-cirrhotic NASH therapeutic trials by Ratziu, Vlad

“…Non-alcoholic steatohepatitis is a disease without a single, specific, diagnostic marker, hence multiple indicators are required to measure therapeutic…”
Get full text

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis by Newsome, Philip N, Buchholtz, Kristine, Cusi, Kenneth, Linder, Martin, Okanoue, Takeshi, Ratziu, Vlad, Sanyal, Arun J, Sejling, Anne-Sophie, Harrison, Stephen A

“…Patients with nonalcoholic steatohepatitis were randomly assigned to receive subcutaneous semaglutide or placebo. The incidence of NASH resolution was…”
Get full text

Why Do So Many Nonalcoholic Steatohepatitis Trials Fail? by Ratziu, Vlad, Friedman, Scott L.

Get full text

Breakthroughs in therapies for NASH and remaining challenges by Ratziu, Vlad, Francque, Sven, Sanyal, Arun

“…Initially a condition that received limited recognition and whose clinical impact was controversial, non-alcoholic steatohepatitis (NASH) has become a leading…”
Get full text

A multisociety Delphi consensus statement on new fatty liver disease nomenclature by Rinella, Mary E, Lazarus, Jeffrey V, Ratziu, Vlad, Francque, Sven M, Sanyal, Arun J, Kanwal, Fasiha, Romero, Diana, Abdelmalek, Manal F, Anstee, Quentin M, Arab, Juan Pablo, Arrese, Marco, Bataller, Ramon, Beuers, Ulrich, Boursier, Jerome, Bugianesi, Elisabetta, Byrne, Christopher D, Castro Narro, Graciela E, Chowdhury, Abhijit, Cortez-Pinto, Helena, Cryer, Donna R, Cusi, Kenneth, El-Kassas, Mohamed, Klein, Samuel, Eskridge, Wayne, Fan, Jiangao, Gawrieh, Samer, Guy, Cynthia D, Harrison, Stephen A, Kim, Seung Up, Koot, Bart G, Korenjak, Marko, Kowdley, Kris V, Lacaille, Florence, Loomba, Rohit, Mitchell-Thain, Robert, Morgan, Timothy R, Powell, Elisabeth E, Roden, Michael, Romero-Gómez, Manuel, Silva, Marcelo, Singh, Shivaram Prasad, Sookoian, Silvia C, Spearman, C Wendy, Tiniakos, Dina, Valenti, Luca, Vos, Miriam B, Wong, Vincent Wai-Sun, Xanthakos, Stavra, Yilmaz, Yusuf, Younossi, Zobair, Hobbs, Ansley, Villota-Rivas, Marcela, Newsome, Philip N

“…The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This…”
Get full text

Advancing the global public health agenda for NAFLD: a consensus statement by Lazarus, Jeffrey V., Arab, Juan Pablo, Castera, Laurent, Cortez-Pinto, Helena, Cusi, Kenneth, Francque, Sven, Hunyady, Bela, Kalamitsis, George, Kao, Jia-Horng, Kaplan, Lee, Kawaguchi, Takumi, Khader, Yousef, Kim, Seung Up, Kodjoh, Nicolas, Koek, Ger, Komas, Narcisse Patrice, Kugelmas, Marcelo, Labidi, Asma, Lavine, Joel E., Lazo, Mariana, Huang, Terry T.-K., Long, Michelle T., Marchesini, Giulio, Nlombi, Charles Mbendi, Milovanovic, Tamara, Musso, Carla, Nakajima, Atsushi, Nava, Edna, Nikolova, Dafina, Norris, Suzanne, Novak, Katja, Kautz, Achim, Papatheodoridis, George, Patel, Keyur, Figueroa, Marlene Pérez, Puri, Puneet, Pan, Calvin Q., Rac, Marek, Alvares-da-Silva, Mario Reis, Roberts, Stuart, Roden, Michael, Rouabhia, Samir, Salupere, Riina, Seki, Yosuke, Serme, Abdel Karim, Shaw, Jonathan E., Shenoy, Thrivikrama, Silva, Marcelo, Skrypnyk, Igor, Socha, Piotr, Newsome, Philip N., Spearman, C. Wendy, Sridharan, Kannan, Sung, Ki-Chul, Swain, Mark, Tan, Soek-Siam, Thiele, Maja, Tolmane, Ieva, Treeprasertsuk, Sombat, Ocama, Ponsiano, Vesterhus, Mette, Wild, Sarah H., Xanthakos, Stavra, Zheng, Kenneth I., Zeybel, Mudjat, Ratziu, Vlad, Zheng, Ming-Hua, Rinella, Mary, Romero, Diana, Adams, Leon, Murillo, Omar Alfaro, Alswat, Khalid, Arrese, Marco, Awuku, Yaw Asante, Baatarkhuu, Oidov, Bakieva, Shokhista, Basu, Rita, Bedri, Shahinaz, Bourliere, Marc, Bugianesi, Elisabetta, Buti, Maria, Byrne, Christopher D., Carrieri, Patrizia, Corey, Kathleen, Craxi, Antonio, Cryer, Donna, Dassanayake, Anuradha, Martins, Antonieta de Ascenção Soares, de Ledinghen, Victor, Dillon, John, Duseja, Ajay, Esmat, Gamal, Fan, Jian-Gao, Farpour-Lambert, Nathalie, Flisiak, Robert, Fuchs, Michael, Gani, Rino A., Ghazinyan, Hasmik, Grønbæk, Henning, Gulnara, Aghayeva

“…© Springer Nature Limited 2021, corrected publication 2021 Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects…”
Get full text

Relationship Among Fatty Liver, Specific and Multiple‐Site Atherosclerosis, and 10‐Year Framingham Score by Pais, Raluca, Redheuil, Alban, Cluzel, Philippe, Ratziu, Vlad, Giral, Philippe

“…Despite a well‐documented increase in the prevalence of subclinical atherosclerosis in patients with steatosis, the relationship among steatosis and…”
Get full text

Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis by McPherson, Stuart, Hardy, Tim, Dufour, Jean-Francois, Petta, Salvatore, Romero-Gomez, Manuel, Allison, Mike, Oliveira, Claudia P, Francque, Sven, Van Gaal, Luc, Schattenberg, Jörn M, Tiniakos, Dina, Burt, Alastair, Bugianesi, Elisabetta, Ratziu, Vlad, Day, Christopher P, Anstee, Quentin M

“…Non-invasive fibrosis scores are widely used to identify/exclude advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). However, these…”
Get full text

Nutrition and physical activity in NAFLD：An overview of the epidemiological evidence by Zelber-Sagi, Shira, Ratziu, Vlad, Oren, Ran

“…Nonalcoholic fatty liver disease（NAFLD）has been recognized as a major health burden.The high prevalence of NAFLD is probably due to the contemporary epidemics…”
Get full text

From NAFLD in clinical practice to answers from guidelines by Nascimbeni, Fabio, Pais, Raluca, Bellentani, Stefano, Day, Christopher Paul, Ratziu, Vlad, Loria, Paola, Lonardo, Amedeo

“…Summary This review of the literature consists of three sections. First, papers concerning non-alcoholic fatty liver disease (NAFLD) awareness among the…”
Get full text

Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis by Loomba, Rohit, Ratziu, Vlad, Harrison, Stephen A., Loomba, Rohit, McFarlane, Stefanie C., Tamaki, Nobuharu, Ratziu, Vlad, Abdelmalek, Manal F., Rinella, Mary E., Anstee, Quentin M., Younossi, Zobair M., Sanyal, Arun, Jairath, Vipul, Harrison, Stephen A.

Get full text

The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials by Sanyal, Arun J., Harrison, Stephen A., Ratziu, Vlad, Abdelmalek, Manal F., Diehl, Anna Mae, Caldwell, Stephen, Shiffman, Mitchell L., Aguilar Schall, Raul, Jia, Catherine, McColgan, Bryan, Djedjos, C. Stephen, McHutchison, John G., Subramanian, G. Mani, Myers, Robert P., Younossi, Zobair, Muir, Andrew J., Afdhal, Nezam H., Bosch, Jaime, Goodman, Zachary

“…Progression of nonalcoholic steatohepatitis (NASH) is incompletely characterized. We analyzed data on longitudinal changes in liver histology, hepatic venous…”
Get full text

Hepatoprotective effects of the dual peroxisome proliferator‐activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis by Staels, Bart, Rubenstrunk, Anne, Noel, Benoit, Rigou, Géraldine, Delataille, Philippe, Millatt, Lesley J., Baron, Morgane, Lucas, Anthony, Tailleux, Anne, Hum, Dean W., Ratziu, Vlad, Cariou, Bertrand, Hanf, Rémy

“…Nonalcoholic fatty liver disease (NAFLD) covers a spectrum of liver damage ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, and…”
Get full text

Endpoints and clinical trial design for nonalcoholic steatohepatitis by Sanyal, Arun J., Brunt, Elizabeth M., Kleiner, David E., Kowdley, Kris V., Chalasani, Naga, Lavine, Joel E., Ratziu, Vlad, McCullough, Arthur

“…Nonalcoholic fatty liver disease is a common cause of chronic liver disease in the general population. Nonalcoholic steatohepatitis (NASH), the aggressive form…”
Get full text

TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial by Loomba, Rohit, Mohseni, Rizwana, Lucas, K. Jean, Gutierrez, Julio A., Perry, Robert G., Trotter, James F., Rahimi, Robert S., Harrison, Stephen A., Ajmera, Veeral, Wayne, Jeffrey D., O’Farrell, Marie, McCulloch, William, Grimmer, Katharine, Rinella, Mary, Wai-Sun Wong, Vincent, Ratziu, Vlad, Gores, Gregory J., Neuschwander-Tetri, Brent A., Kemble, George

“…Increased de novo lipogenesis creates excess intrahepatic fat and lipotoxins, propagating liver damage in nonalcoholic steatohepatitis. TVB-2640, a fatty acid…”
Get full text

Hepatitis C infection and risk of diabetes: A systematic review and meta-analysis by White, Donna L, Ratziu, Vlad, El-Serag, Hashem B

“…Background/Aims Several studies found hepatitis C (HCV) increases risk of Type II diabetes mellitus (DM). However, others found no or only sub-group specific…”
Get full text

Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD by Brunt, Elizabeth M., Clouston, Andrew D., Goodman, Zachary, Guy, Cynthia, Kleiner, David E., Lackner, Carolin, Tiniakos, Dina G., Wee, Aileen, Yeh, Matthew, Leow, Wei Qiang, Chng, Elaine, Ren, Yayun, Boon Bee, George Goh, Powell, Elizabeth E., Rinella, Mary, Sanyal, Arun J., Neuschwander-Tetri, Brent, Younossi, Zobair, Charlton, Michael, Ratziu, Vlad, Harrison, Stephen A., Tai, Dean, Anstee, Quentin M.

“…Histologically assessed hepatocyte ballooning is a key feature discriminating non-alcoholic steatohepatitis (NASH) from steatosis (NAFL). Reliable…”
Get full text

A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe by Lazarus, Jeffrey V., Ekstedt, Mattias, Marchesini, Giulio, Mullen, Jillian, Novak, Katja, Pericàs, Juan M., Roel, Elena, Romero-Gómez, Manuel, Ratziu, Vlad, Tacke, Frank, Cortez-Pinto, Helena, Anstee, Quentin M.

“…[Display omitted] •A comprehensive public health response to NAFLD is lacking in the 29 countries.•Major gaps include strategies, clinical guidelines,…”
Get full text

Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial by Sanyal, Arun J., Lopez, Patricia, Lawitz, Eric J., Lucas, Kathryn J., Loeffler, Juergen, Kim, Won, Goh, George B. B., Huang, Jee-Fu, Serra, Carla, Andreone, Pietro, Chen, Yi-Cheng, Hsia, Stanley H., Ratziu, Vlad, Aizenberg, Diego, Tobita, Hiroshi, Sheikh, Aasim M., Vierling, John M., Kim, Yoon Jun, Hyogo, Hideyuki, Tai, Dean, Goodman, Zachary, Schaefer, Felicity, Carbarns, Ian R. I., Lamle, Sophie, Martic, Miljen, Naoumov, Nikolai V., Brass, Clifford A.

“…The multimodal activities of farnesoid X receptor (FXR) agonists make this class an attractive option to treat nonalcoholic steatohepatitis. The safety and…”
Get full text

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science by Siddiqui, Mohammad Shadab, Harrison, Stephen A., Abdelmalek, Manal F., Anstee, Quentin M., Bedossa, Pierre, Castera, Laurent, Dimick‐Santos, Lara, Friedman, Scott L., Greene, Katherine, Kleiner, David E., Megnien, Sophie, Neuschwander‐Tetri, Brent A., Ratziu, Vlad, Schabel, Elmer, Miller, Veronica, Sanyal, Arun J.

“…Nonalcoholic steatohepatitis (NASH) is an important cause of liver‐related morbidity and mortality. There are no approved therapies, and the results of…”
Get full text